{
    "nct_id": "NCT00630851",
    "title": "A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility",
    "status": "COMPLETED",
    "last_update_time": "2015-03-04",
    "description_brief": "The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Aricept (donepezil) \u2014 acetylcholinesterase inhibitor"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests Aricept (brand name) in severe Alzheimer\u2019s patients living in assisted care, measuring global/cognitive/behavioural/ADL outcomes over six months. Aricept is donepezil, a specific, reversible acetylcholinesterase inhibitor that increases acetylcholine and is used for symptomatic treatment of cognitive impairment in Alzheimer\u2019s disease. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Key extracted details \u2014 drug: Aricept (donepezil); drug type/mechanism: acetylcholinesterase inhibitor (small molecule); trial design: 6-month, multicenter, double-blind, parallel, placebo-controlled in nursing-home/assisted-care patients with severe AD; measured effects: global, behavioural, ADL, tolerability. The cited nursing-home RCT and subsequent responder analyses support that donepezil\u2019s main effects are symptomatic (cognitive/global stabilization or modest improvement), not disease modification. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search4\ue201",
        "Reflect: Classification rationale \u2014 donepezil is a small-molecule symptomatic treatment that enhances cholinergic neurotransmission to improve/maintain cognition and global function; it does not target core AD pathology (amyloid or tau) as a disease-modifying biologic or small-molecule anti-pathology agent. Although the trial also assesses behavioural/ADL outcomes, the mechanism and primary intent align with the \"cognitive enhancer\" category. No stronger alternative category fits. \ue200cite\ue202turn0search3\ue201",
        "Web search results (selected supporting sources): 1) RCT of donepezil in nursing homes \u2014 randomized 24-week trial showing cognitive/global benefit and safety in nursing-home AD patients. \ue200cite\ue202turn0search0\ue201 2) Responder analysis of donepezil in severe AD showing stabilization/improvement across cognitive and functional measures. \ue200cite\ue202turn0search1\ue201 3) Evidence review describing donepezil as a specific, reversible acetylcholinesterase inhibitor used for symptomatic cognitive treatment in AD. \ue200cite\ue202turn0search3\ue201 4) Popular-summary article reporting modest benefits of Aricept in severe AD (supporting the 6-month severe-AD study). \ue200cite\ue202turn0search4\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests Aricept (donepezil), a well-characterized, reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine to enhance cholinergic neurotransmission and produce symptomatic cognitive/global benefits in AD. This mechanism is a modulation of neurotransmitter signaling rather than targeting amyloid, tau, inflammation, or other core pathological pathways. \ue200cite\ue202turn0search9\ue202turn0search2\ue201",
        "Act: Extracted details \u2014 drug: Aricept (donepezil); mechanism: reversible acetylcholinesterase (AChE) inhibitor (small molecule) that enhances cholinergic neurotransmission; trial design/endpoints: 6-month, multicenter, double-blind, parallel, placebo-controlled in nursing-home/assisted-care or severe-AD patients with outcomes measuring global/cognitive/behavioral/ADL function and tolerability. Key clinical trials and reviews document symptomatic cognitive and global benefits in nursing-home and severe AD populations. \ue200cite\ue202turn0search0\ue202turn0search4\ue202turn0search11\ue201",
        "Reflect: Classification rationale \u2014 CADRO category D) Neurotransmitter Receptors best fits because donepezil\u2019s primary action is to augment cholinergic neurotransmission (a neurotransmitter system), i.e., symptomatic modulation of synaptic signaling. It is not a disease-modifying anti-amyloid or anti-tau intervention, nor does the trial evaluate a diagnostic-only procedure. Therefore D) is the most specific and appropriate category. Supporting evidence (mechanistic reviews and RCTs) confirms this interpretation. \ue200cite\ue202turn0search9\ue202turn0search0\ue201",
        "Web search results (selected supporting sources): 1) Randomized 24-week nursing-home trial of donepezil showing cognitive/global benefit and tolerability in nursing-home AD patients. \ue200cite\ue202turn0search0\ue201 2) Multinational 24-week trial showing donepezil preserves cognition and global function in severe AD. \ue200cite\ue202turn0search4\ue201 3) Reviews summarizing donepezil as a specific, reversible acetylcholinesterase inhibitor used for symptomatic treatment of AD. \ue200cite\ue202turn0search9\ue202turn0search2\ue201 4) Systematic reviews/meta-analyses confirming modest short-to-medium term cognitive and global benefits of donepezil across AD severities. \ue200cite\ue202turn0search11\ue202turn0search3\ue201"
    ]
}